Ionis Pharmaceuticals, Inc. (IONS) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $73.28: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10 and A.R:R 4.5:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 14%; Below-average business quality; Below long-term trend.
Ionis Pharmaceuticals is a fully integrated commercial-stage biotech with seven marketed RNA-targeted medicines treating rare and serious diseases, including SPINRAZA and QALSODY (Biogen-partnered) and independently commercialized TRYNGOLZA and DAWNZERA. Revenue was $944M in... Read more
Sell if holding. Engine safety override at $73.28: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10 and A.R:R 4.5:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 14%; Below-average business quality; Below long-term trend. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.6/10, moderate confidence.
Passes 6/8 gates (favorable risk/reward ratio, clean insider activity, news events none recent, earnings proximity 53d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: moderate.
Recent developments
updated 2026-06-13Recent Developments — Ionis Pharmaceuticals, Inc.
Latest news
- NEWS TD Cowen Reiterates Buy on Ionis Pharmaceuticals, Maintains $108 Price Target — benzinga Jun 15, 2026 positive
- NEWS Intellia's One-Time Gene Editing Therapy Gains Ground Against Rivals In Rare Swelling Disorder — benzinga Jun 15, 2026 positive
- NEWS Ionis To Present New Analyses From CORE And CORE2 Pivotal Studies Supporting Olezarsen For Severe Hypertriglyceridemia A — benzinga Jun 4, 2026 positive
- NEWS HC Wainwright & Co. Reiterates Buy on Ionis Pharmaceuticals, Maintains $125 Price Target — benzinga Jun 1, 2026 positive
- NEWS Citigroup Initiates Coverage On Ionis Pharmaceuticals with Buy Rating, Announces Price Target of $115 — benzinga May 19, 2026 positive
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHcounterpartyBiogen10-K Item 1A: 'We depend on our collaborations with Biogen for the development and commercialization of SPINRAZA and QALSODY.'
Material Events(8-K, last 90d)
- 2026-03-09Item 5.02LOWB. Lynne Parshall and Lead Independent Director Joseph H. Wender both notified the Company on March 3, 2026 they will retire from the Board and not seek re-election at the 2026 Annual Meeting. Peter N. Reikes announced as new director appointee. No disagreements cited.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Clinical-stage biotech: losses expected pre-commercialisation. Quality floor doesn't distinguish R&D investment from operational decay — components above tell the real story.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $73.28: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10 and A.R:R 4.5:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 14%; Below-average business quality; Below long-term trend. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $69.77. Score 5.6/10, moderate confidence.
Take-profit target: $91.95 (+25.5% upside). Prior stop was $69.77. Stop-loss: $69.77.
Concentration risk — Counterparty: Biogen; Quality below floor (1.8 < 4.0).
Ionis Pharmaceuticals, Inc. trades at a P/E of N/A (forward -115.4). TrendMatrix value score: 6.4/10. Verdict: Sell.
33 analysts cover IONS with a consensus score of 4.1/5. Average price target: $102.
What does Ionis Pharmaceuticals, Inc. do?Ionis Pharmaceuticals is a fully integrated commercial-stage biotech with seven marketed RNA-targeted medicines...
Ionis Pharmaceuticals is a fully integrated commercial-stage biotech with seven marketed RNA-targeted medicines treating rare and serious diseases, including SPINRAZA and QALSODY (Biogen-partnered) and independently commercialized TRYNGOLZA and DAWNZERA. Revenue was $944M in 2025; key revenue streams include product sales and royalties from partnered drugs.